Article Text

Download PDFPDF

PO.7.157 Does remission according DORIS 2021 match the treating rheumatologist judgement? Analylis at recruitment of a prospective study of 500 SLE patients from a Spanish multicenter cohort
  1. I Altabás González1,
  2. Í Rúa-Figueroa2,
  3. F Rubiño Juarez2,
  4. C Mouriño1,
  5. I Hernández1,
  6. R Almagro3,
  7. E Uriarte Isacelaya4,
  8. E Tomero Muriel5,
  9. T Salman6,
  10. I Carrión-Barberà6,
  11. M Galindo7,
  12. M Rodríguez Almaraz7,
  13. N Jiménez8,
  14. L Inês9 and
  15. JM Pego-Reigosa1
  1. 1Complejo Hospitalario Universitario de Vigo ~ Spain
  2. 2Hospital Universitario de Gran Canaria Doctor Negrín ~ Las Palmas de Gran Canaria ~ Spain
  3. 3Hospital Universitario de Jerez de la Frontera ~ Cádiz ~ Spain
  4. 4Hospital Universitario de Donostia ~ San Sebastián ~ Spain
  5. 5Hospital Universitario de la Princesa ~ Madrid ~ Spain
  6. 6Hospital del Mar ~ Barcelona ~ Spain
  7. 7Hospital Universitario 12 de Octubre ~ Madrid ~ Spain
  8. 8Grupo IRIDIS ~ Vigo ~ Spain
  9. 9Centro Hospitalar e Universitario de Coimbra ~ Portugal


Introduction An accurate target in Systemic Lupus Erythematosus (SLE) Treat to Target strategies has been challenging over the past years. Recently, a new definition of remission was updated in 2021 by the international DORIS (Definition of Remission in SLE) taskforce.

Objective To quantify the proportion of patients who achieve DORIS and evaluate the agreement between DORIS and the treating rheumatologist judgement.

Methods Prospective multicenter study of SLE patients (ACR 1997 Classification Criteria or Clinical diagnosis by the Physician) from seven Spanish Rheumatology Departments. DORIS 2021 remission definition was applied and the rheumatologists were asked to classified the activity of the disease in 5 different categories: remission, serologically active clinically quiescent (SACQ), low, moderate or high activity. Statistical analysis: descriptive cross-sectional (at the time of recruitment) analysis was done. Analysis of the level of agreement between expert opinion and the definition of remission was evaluated using Cohen’s kappa. The reasons of disagreement were evaluated.

Results A total of 508 patients were included (92% women; mean age (±SD): 50.4 years (±SD 13.7)). Table 1 shows in detail the patients characteristics at baseline. Two hundred and sixty-seven (54.4%) patients were in DORIS 2021 remission. According to the rheumatologist judgement, 206 (41.6%) patients were considered in remission and 71 (14.3%) in a SACQ state (Figure 1). Overall agreement between rheumatologist opinion and DORIS was 81.28% (95% CI: 79.9, 82.9) with a Cohen’s kappa of 0.62. We found disagreement in 46 patients, and the main reasons were a clinical SLEDAI>0 in 39 (84.8%) patients; Physician Global Assessment (PGA) >0.5 in 5 patients and a prednisone dose above 5 mg day in other five patients.

Abstract PO.7.157 Table 1

Patient demographics and disease characteristics

Abstract PO.7.157 Figure 1

Concordance of DORIS and physician remission

Conclusion At a given point in time, more than half of SLE patients were in DORIS 2021 remission. The overall agreement between rheumatologist opinion and DORIS remission is accurate.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.